ZA201303687B - Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer - Google Patents

Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Info

Publication number
ZA201303687B
ZA201303687B ZA2013/03687A ZA201303687A ZA201303687B ZA 201303687 B ZA201303687 B ZA 201303687B ZA 2013/03687 A ZA2013/03687 A ZA 2013/03687A ZA 201303687 A ZA201303687 A ZA 201303687A ZA 201303687 B ZA201303687 B ZA 201303687B
Authority
ZA
South Africa
Prior art keywords
inhibitor
compositions
treating cancer
pi3k
mek
Prior art date
Application number
ZA2013/03687A
Other languages
English (en)
Inventor
Laurent Debussche
Carlos Garcia-Escheverria
Jianguo Ma
Stuart Mcmillan
Janet Anne Meurer Ogden
Loic Vincent
Original Assignee
Sanofi Sa
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201303687(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa, Merck Patent Gmbh filed Critical Sanofi Sa
Publication of ZA201303687B publication Critical patent/ZA201303687B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2013/03687A 2010-12-09 2013-05-21 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer ZA201303687B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42146510P 2010-12-09 2010-12-09
US201161436258P 2011-01-26 2011-01-26
US201161467485P 2011-03-25 2011-03-25
FR1159940 2011-11-03
PCT/US2011/063871 WO2012078832A1 (en) 2010-12-09 2011-12-08 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Publications (1)

Publication Number Publication Date
ZA201303687B true ZA201303687B (en) 2014-01-29

Family

ID=45464841

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/03687A ZA201303687B (en) 2010-12-09 2013-05-21 Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer

Country Status (23)

Country Link
US (1) US20140024653A1 (enExample)
EP (1) EP2648729A1 (enExample)
JP (1) JP2013544892A (enExample)
KR (1) KR20140011311A (enExample)
CN (1) CN103402518A (enExample)
AR (1) AR084216A1 (enExample)
AU (1) AU2011338354A1 (enExample)
BR (1) BR112013014198A2 (enExample)
CA (1) CA2820748A1 (enExample)
CL (1) CL2013001643A1 (enExample)
CR (1) CR20130246A (enExample)
DO (1) DOP2013000131A (enExample)
MA (1) MA34815B1 (enExample)
MX (1) MX2013006319A (enExample)
NZ (1) NZ611581A (enExample)
PE (1) PE20140702A1 (enExample)
PH (1) PH12013501163A1 (enExample)
RU (1) RU2013131241A (enExample)
SG (1) SG190368A1 (enExample)
TW (1) TW201306837A (enExample)
UY (1) UY33790A (enExample)
WO (1) WO2012078832A1 (enExample)
ZA (1) ZA201303687B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334192A (zh) * 2012-04-06 2015-02-04 赛诺菲 使用pi3k抑制剂和mek抑制剂治疗癌症的方法
US20150297594A1 (en) * 2012-10-11 2015-10-22 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
WO2016014390A1 (en) * 2014-07-25 2016-01-28 Merck Patent Gmbh Compositions and methods for mek inhibitor combination therapy in the treatment of cancer
CA3085693A1 (en) * 2017-12-22 2019-06-27 Adienne S.A. Quantitative cellular method for determining the biological activity of an anti-cd26 ligand
JP2022547358A (ja) 2019-09-13 2022-11-14 ジ インスティテュート オブ キャンサー リサーチ：ロイヤル キャンサー ホスピタル 治療組成物、組み合わせ、及び使用方法
US20230414626A1 (en) * 2020-10-16 2023-12-28 Memorial Sloan Kettering Cancer Center Induction of ferroptosis for cancer therapy
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Also Published As

Publication number Publication date
CL2013001643A1 (es) 2014-03-28
AR084216A1 (es) 2013-05-02
KR20140011311A (ko) 2014-01-28
AU2011338354A1 (en) 2013-06-27
NZ611581A (en) 2015-02-27
MA34815B1 (fr) 2014-01-02
JP2013544892A (ja) 2013-12-19
SG190368A1 (en) 2013-06-28
RU2013131241A (ru) 2015-01-20
TW201306837A (zh) 2013-02-16
WO2012078832A1 (en) 2012-06-14
EP2648729A1 (en) 2013-10-16
CN103402518A (zh) 2013-11-20
PE20140702A1 (es) 2014-06-26
UY33790A (es) 2012-07-31
PH12013501163A1 (en) 2013-07-29
CR20130246A (es) 2013-09-03
MX2013006319A (es) 2013-07-03
US20140024653A1 (en) 2014-01-23
CA2820748A1 (en) 2012-06-14
BR112013014198A2 (pt) 2016-09-13
DOP2013000131A (es) 2013-11-15

Similar Documents

Publication Publication Date Title
LT2556071T (lt) Kinazės inhibitoriai ir jų panaudojimas vėžio gydymui
IL229876B (en) Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
PT2483278E (pt) Compostos de bezoxazepina inibidores de pi3k e a sua utilização no tratamento do cancro
IL227429A0 (en) The components and methods of cancer treatment
ZA201404552B (en) Benzoxepin pi3k inhibitor compound and use thereof
ZA201303687B (en) Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer
PL2532680T3 (pl) Kompozycja medyczna do leczenia raka i/lub zapobiegania
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL218987A0 (en) Methods and compositions for treating cancer
PH12012500709A1 (en) Combinations of a pi3k inhibitor and a mek inhibitor
PL2532366T3 (pl) Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2655309A4 (en) METHODS AND COMPOSITIONS FOR TREATING LUNG CANCER
EP2534145A4 (en) THERAPEUTIC METHODS AND COMPOSITIONS INVOLVING THE INHIBITION OF ALLOSTERIC KINASE
PT2632452T (pt) Compostos e composições para o tratamento do cancro
IL232353B (en) An inhibitor of the nedd8 mecatenase and a hypomethylated agent for use in cancer therapy
EP2556820A4 (en) COMPOSITION CONTAINING PDE5 INHIBITOR FOR MITIGATION OF SKIN WRINKLES
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
EP2608790A4 (en) PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
IL229231A0 (en) Preparations and methods for the treatment of cancer
EP2593111A4 (en) NEW COMPOUNDS FOR THE TREATMENT OF CANCER AND OTHER DISEASES
ZA201305497B (en) Methods and compositions for preventing and treating osteoarthritis
EP2537031A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
PT2658536T (pt) Gemcabeno e derivados para tratamento da pancreatite
ZA201207797B (en) Injectable formulation of a reverse transcriptase inhibitor for the treatment cancer